You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

SPARC gains on antibody licensing agreement with Biomodifying

Capital Market 

Sun Pharma Advanced Research Company (SPARC) gained 2.54% to Rs 254.80 after the company said that it has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target.

In an exchange filing made during market hours today, the company said that it has entered into an agreement with Biomodifying LLC to exclusively license Biomodifying's intellectual property, including all patents and patent applications owned or controlled by Biomodifying, along with antibodies developed for multiple uses including for cancer.

Biomodifying, LLC is a biotech company dedicated to identifying and exploiting molecules overexpressed by cancer cells by developing therapies that specifically target tumors while sparing normal, non-cancerous tissues - an approach that is expected to contribute to the development of therapies less harsh and more adapted to larger patient populations than currently used chemotherapy regimens.

Under the agreement, Biomodifying is eligible for an up-front payment, milestone payments on pre-specified clinical, regulatory, and commercial milestones, as well as royalties on sales. In addition, SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP. Anil

Raghavan, CEO of SPARC, said: This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPARC into a company focussed on novel treatment modalities, including bi-specific antibodies and antibody drug conjugates."

SPARC is a clinical stage bio-pharmaceutical company, It was formed in 2007 through a demerger from Sun Pharma, a global leader in speciality generics.

On a standalone basis, Sun Pharma Advanced Research Company (SPARC)'s net loss during Q2 FY22 stood at Rs 55.14 crore as compared to a net loss of Rs 83.49 crore in Q2 FY21. Revenue from operations surged 57.99% to Rs 27.87 crore in Q2 September 2021 as against Rs 17.64 crore in Q2 September 2020.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, December 03 2021. 14:58 IST